Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandor Szunyogh

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 23, 2025
Recent developments in gene therapy for Parkinson's diseaseSandor Szunyogh, Emily Carroll, Richard Wade-Martins
Chembiochem : a European Journal of Chemical Biology|July 17, 2020
HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*Matthias Schiedel, Attila Lehotzky, Sandor Szunyogh, et al.
Iscience|July 1, 2026
Dysregulation of sphingolipid-metabolizing enzymes in Friedreich's ataxia: <i>In vitro</i> and <i>in vivo</i> insights into therapeutic targetingZenouska Ramchunder, Ester Kalef-Ezra, Saqlain Suleman, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 23, 2025
Recent developments in gene therapy for Parkinson's diseaseSandor Szunyogh, Emily Carroll, Richard Wade-Martins
Chembiochem : a European Journal of Chemical Biology|July 17, 2020
HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*Matthias Schiedel, Attila Lehotzky, Sandor Szunyogh, et al.
Iscience|July 1, 2026
Dysregulation of sphingolipid-metabolizing enzymes in Friedreich's ataxia: <i>In vitro</i> and <i>in vivo</i> insights into therapeutic targetingZenouska Ramchunder, Ester Kalef-Ezra, Saqlain Suleman, et al.
Pageof 1